Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
Add more filters










Publication year range
1.
Eur Neuropsychopharmacol ; 49: 93-100, 2021 08.
Article in English | MEDLINE | ID: mdl-33882433

ABSTRACT

The diagnosis and treatment of bipolar depression (BDep) poses complex clinical challenges for psychiatry. Proton magnetic resonance spectroscopy (1H-MRS) is a useful imaging tool for investigating in vivo levels of brain neuro-metabolites, critical to understanding the process of mood dysregulation in Bipolar Disorder. Few studies have evaluated longitudinal clinical outcomes in BDep associated with 1H-MRS metabolic changes. This study aimed to longitudinally assess brain 1H-MRS metabolites in the anterior cingulate cortex (ACC) correlated with improvement in depression (from BDep to euthymia) after lithium treatment in BDep patients versus matched healthy controls (HC). Twenty-eight medication-free BDep patients and 28 HC, matched for age and gender, were included in this study. All subjects were submitted to a 3-Tesla brain 1H-MRS scan in the ACC using a single-voxel (8cm3) PRESS sequence at baseline. At follow-up (6 weeks), 14 BDep patients repeated the exam in euthymia. Patients with current BDep had higher baseline Myo-inositol/Cr (mI/Cr) and Choline/Cr (Cho/Cr) compared to HC. After six weeks, mI/Cr or Cho/Cr levels in subjects that achieved euthymia no longer differed to levels in HC, while high Cho/Cr levels persisted in non-responders . Elevated ACC mI/Cr and Cho/Cr in BDep might indicate increased abnormal membrane phospholipid metabolism and phosphatidylinositol (PI) cycle activity. Return of mI/Cr and Cho/Cr to normal levels after lithium-induced euthymia suggests a critical regulatory effect of lithium targeting the PI cycle involved in mood regulation.


Subject(s)
Bipolar Disorder , Aspartic Acid/metabolism , Bipolar Disorder/diagnostic imaging , Bipolar Disorder/drug therapy , Brain/metabolism , Choline/metabolism , Choline/pharmacology , Choline/therapeutic use , Creatine/metabolism , Gyrus Cinguli/metabolism , Humans , Inositol/metabolism , Lithium/therapeutic use , Proton Magnetic Resonance Spectroscopy/methods
2.
Transl Psychiatry ; 7(4): e1086, 2017 04 11.
Article in English | MEDLINE | ID: mdl-28398341

ABSTRACT

Calcium channels control the inflow of calcium ions into cells and are involved in diverse cellular functions. The CACNA1C gene polymorphism rs1006737 A allele has been strongly associated with increased risk for bipolar disorder (BD) and with modulation of brain morphology. The medial prefrontal cortex (mPFC) has been widely associated with mood regulation in BD, but the role of this CACNA1C polymorphism in mPFC morphology and brain aging has yet to be elucidated. One hundred seventeen euthymic BD type I subjects were genotyped for CACNA1C rs1006737 and underwent 3 T three-dimensional structural magnetic resonance imaging scans to determine cortical thickness of mPFC components (superior frontal cortex (sFC), medial orbitofrontal cortex (mOFC), caudal anterior cingulate cortex (cACC) and rostral anterior cingulate cortex (rACC)). Carriers of the CACNA1C allele A exhibited greater left mOFC thickness compared to non-carriers. Moreover, CACNA1C A carriers showed age-related cortical thinning of the left cACC, whereas among A non-carriers there was not an effect of age on left cACC cortical thinning. In the sFC, mOFC and rACC (left or right), a negative correlation was observed between age and cortical thickness, regardless of CACNA1C rs1006737 A status. Further studies investigating the direct link between cortical thickness, calcium channel function, apoptosis mechanism and their underlying relationship with aging-associated cognitive decline in BD are warranted.


Subject(s)
Alleles , Bipolar Disorder/genetics , Bipolar Disorder/pathology , Calcium Channels, L-Type/genetics , Genetic Predisposition to Disease/genetics , Prefrontal Cortex/pathology , Adolescent , Adult , Age Factors , Bipolar Disorder/diagnostic imaging , Dominance, Cerebral/genetics , Dominance, Cerebral/physiology , Female , Genetic Carrier Screening , Humans , Imaging, Three-Dimensional , Magnetic Resonance Imaging , Male , Polymorphism, Genetic/genetics , Prefrontal Cortex/diagnostic imaging , Statistics as Topic , Young Adult
3.
Acta Psychiatr Scand ; 133(3): 214-20, 2016 Mar.
Article in English | MEDLINE | ID: mdl-26513535

ABSTRACT

OBJECTIVE: The objective of this study was to evaluate brain lithium levels using (7) Li magnetic resonance spectroscopy after 6 weeks of lithium therapy in bipolar depression to test the hypothesis that brain and plasma lithium are correlated. It was also tested whether responders and remitters have different pharmacokinetics, blood and brain lithium levels (ratio) compared with those presenting suboptimal antidepressant improvement. METHOD: Twenty-three patients with bipolar disorder (I and II) during depressive episodes were included and followed up for 6 weeks at the University of Sao Paulo using flexible dose of lithium (450-900 mg/day). Sixteen patients were drug-naïve. At endpoint, patients underwent a (7) Li-MRS scan and brain lithium concentrations were calculated. RESULTS: A significant association between central and peripheral lithium levels was found only in remitters (r = 0.7, P = 0.004) but not in non-remitters (r = -0.12, P = 0.76). Also, brain lithium (but not plasma) was inversely correlated with age (r = -0.46, P = 0.025). Plasma lithium did not correlate with any clinical outcome, lithium dosage or adverse effects. CONCLUSION: These findings suggest that non-remitters may not transport lithium properly to the brain, which may underlie treatment resistance to lithium in BD. Future studies with (7) Li-MRS integrated with the evaluation of blood-brain barrier transport mechanisms and longitudinal clinical outcomes in BD and aging are warranted.


Subject(s)
Antimanic Agents/pharmacokinetics , Bipolar Disorder/metabolism , Brain/metabolism , Depression/metabolism , Lithium Compounds/pharmacokinetics , Adult , Antimanic Agents/therapeutic use , Bipolar Disorder/blood , Bipolar Disorder/drug therapy , Blood-Brain Barrier/metabolism , Brain/drug effects , Depression/blood , Depression/drug therapy , Female , Humans , Lithium Compounds/therapeutic use , Magnetic Resonance Spectroscopy/methods , Male
4.
Neuromuscul Disord ; 25(5): 371-4, 2015 May.
Article in English | MEDLINE | ID: mdl-25770920

ABSTRACT

Here we summarize the clinical history of Ringo, a golden retriever muscular dystrophy (GRMD) dog, who had a mild phenotype despite the absence of muscle dystrophin. Ringo died of cardiac arrest at age 11 and therefore displayed a normal lifespan. One of his descendants, Suflair, born April 2006, also displays a mild course. Dystrophin analysis confirmed total absence of muscle dystrophin in both dogs. Muscle utrophin expression did not differ from severely affected GRMD dogs. Finding what protects these special dogs from the dystrophic degeneration process is now a great challenge that may open new avenues for treatment. But most importantly, the demonstration that it is possible to have a functional muscle, in a medium-large animal even in the absence of dystrophin, brings new hope for Duchenne patients.


Subject(s)
Dog Diseases/metabolism , Dystrophin/metabolism , Muscle, Skeletal/metabolism , Muscular Dystrophy, Animal/metabolism , Animals , Dogs , Muscular Dystrophy, Duchenne/etiology , Phenotype
5.
Lupus ; 23(14): 1500-11, 2014 Dec.
Article in English | MEDLINE | ID: mdl-25135060

ABSTRACT

INTRODUCTION: Creatine supplementation has emerged as a promising non-pharmacological therapeutic strategy to counteract muscle dysfunction and low lean mass in a variety of conditions, including in pediatric and rheumatic diseases. The objective of this study was to examine the efficacy and safety of creatine supplementation in childhood systemic lupus erythematosus (C-SLE). METHODS: C-SLE patients with mild disease activity (n = 15) received placebo or creatine supplementation in a randomized fashion using a crossover, double-blind, repeated-measures design. The participants were assessed at baseline and after 12 weeks in each arm, interspersed by an eight-week washout period. The primary outcomes were muscle function, as assessed by a battery of tests including one-maximum repetition (1-RM) tests, the timed-up-and-go test, the timed-stands test, and the handgrip test. Secondary outcomes included body composition, biochemical markers of bone remodeling, aerobic conditioning, quality of life, and physical capacity. Possible differences in dietary intake were assessed by three 24-hour dietary recalls. Muscle phosphorylcreatine content was measured through phosphorus magnetic resonance spectroscopy (31 P-MRS). The safety of the intervention was assessed by laboratory parameters, and kidney function was measured by (51)Cr-EDTA clearance. Additionally, self-reported adverse events were recorded throughout the trial. RESULTS: Intramuscular phosphorylcreatine content was not significantly different between creatine and placebo before or after the intervention (creatine-Pre: 20.5 ± 2.6, Post: 20.4 ± 4.1, placebo-Pre: 19.8 ± 2.0; Post: 20.2 ± 3.2 mmol/kg wet muscle; p = 0.70 for interaction between conditions). In addition, probably as a consequence of the lack of change in intramuscular phosphorylcreatine content, there were no significant changes between placebo and creatine for any muscle function and aerobic conditioning parameters, lean mass, fat mass, bone mass, and quality of life scores (p > 0.05). The (51)Cr-EDTA clearance was not altered by creatine supplementation and no side effects were noticed. CONCLUSION: A 12-week creatine supplementation protocol at 0.1 g/kg/d is well tolerated and free of adverse effects but did not affect intramuscular phosphorylcreatine, muscle function, free-fat mass or quality of life in non-active C-SLE patients. TRIAL REGISTRATION: Clinicaltrials.gov number: NCT01217320.


Subject(s)
Creatine/therapeutic use , Dietary Supplements , Lupus Erythematosus, Systemic/drug therapy , Lupus Erythematosus, Systemic/physiopathology , Muscle, Skeletal/physiopathology , Adolescent , Anaerobic Threshold , Body Composition , Bone Remodeling/physiology , Child , Creatine/adverse effects , Cross-Over Studies , Dietary Supplements/adverse effects , Double-Blind Method , Exercise Test , Exercise Tolerance , Female , Hand Strength , Humans , Magnetic Resonance Imaging , Male , Muscle, Skeletal/metabolism , Phosphocreatine/metabolism , Quality of Life
6.
AJNR Am J Neuroradiol ; 34(1): 80-4, 2013 Jan.
Article in English | MEDLINE | ID: mdl-22766678

ABSTRACT

BACKGROUND AND PURPOSE: (1)H-MR spectroscopy is a useful tool in brain tumor evaluation. A critical point in obtaining representative spectra is the correct voxel positioning, which can be more accurate after Gd administration. Some experimental data suggested that Gd could cause Cho signal loss. Our aim was to evaluate the effect of Gd in the Cho peak area and width in patients with GBM. MATERIALS AND METHODS: We performed multivoxel (1)H-MR spectroscopy before and after Gd administration in 18 patients with GBM. Quantification of Cho peak area and width in each voxel was completed, and the Cho mean and maximum values before and after Gd injection were calculated in the tumor and contralateral hemisphere. Choline peak area and width values obtained before and after contrast were compared, considering as separate entities enhancing and nonenhancing tumoral voxels and the contralateral hemisphere. RESULTS: No statistically significant differences were found for the Cho peak area mean values in the tumoral voxels or contralaterally (P > .05). A tendency for an increase in the Cho peak width mean value was found in the tumoral enhancing voxels (P = .055). A statistically significant decrease was found for the mean value of the maximum Cho peak area in enhancing tumoral voxels (P = .020). No significant differences were found in the nonenhancing tumoral voxels or contralaterally (P > .05). CONCLUSIONS: The injection of Gd before performing (1)H-MR spectroscopy might not significantly affect the Cho peak area in patients with GBM. The paramagnetic contrast seems to cause a different effect, depending on Gd enhancement.


Subject(s)
Brain Neoplasms/metabolism , Brain/metabolism , Choline/analysis , Contrast Media , Electron Spin Resonance Spectroscopy/methods , Gadolinium , Glioblastoma/metabolism , Adult , Aged , Aged, 80 and over , Brain/drug effects , Brain/pathology , Brain Neoplasms/diagnosis , Contrast Media/administration & dosage , Female , Gadolinium/administration & dosage , Glioblastoma/diagnosis , Humans , Male , Middle Aged , Reproducibility of Results , Sensitivity and Specificity
7.
AJNR Am J Neuroradiol ; 31(7): 1347-9, 2010 Aug.
Article in English | MEDLINE | ID: mdl-20150306

ABSTRACT

CTX is a rare lipid-storage disease. Novel MRS findings from 3 patients, using a short TE, were the presence of lipid peaks at 0.9 and 1.3 ppm in the depth of the cerebellar hemisphere; this might represent an additional marker of disease that is CNS-specific and noninvasive. A decrease in NAA concentration was also detected and attributed to neuroaxonal damage. One patient presented an increase in mIns concentration, pointing to gliosis and astrocytic proliferation.


Subject(s)
Aspartic Acid/analogs & derivatives , Magnetic Resonance Spectroscopy , Xanthomatosis, Cerebrotendinous/metabolism , Xanthomatosis, Cerebrotendinous/pathology , Adult , Aspartic Acid/metabolism , Cerebellum/metabolism , Cerebellum/pathology , Choline/metabolism , Humans , Inositol/metabolism , Lactic Acid/metabolism , Male , Middle Aged , Young Adult
8.
AJNR Am J Neuroradiol ; 28(6): 1071-5; discussion 1076-7, 2007.
Article in English | MEDLINE | ID: mdl-17569960

ABSTRACT

BACKGROUND AND PURPOSE: Malformations of cortical development (MCD) are traditionally considered as a cause of epilepsy. Our aim was to study patients with focal MCD, by using multivoxel proton MR spectroscopy; we focused not only on the lesion but also on the normal-appearing contralateral side (NACS). Our hypothesis was that the metabolic abnormality extends to the NACS; therefore, it would be inadequate to consider NACS as an internal control. MATERIALS AND METHODS: We studied 16 patients with focal MCD. MR spectroscopy was performed by using a point-resolved spectroscopy sequence technique, including the MCD area and the NACS. In each volume of interest, a smaller volume of interest of 2.25 cm(3) centered on the MCD was selected to study the N-acetylaspartate/creatine (NAA/Cr) ratio. In NACS, this ratio was studied by placing a symmetric voxel in comparison with the smaller MCD volume of interest. A control group (n=30) was also studied to evaluate both white and gray matter by using the same MR spectroscopy protocol. RESULTS: From 16 analyzed volumes of interest with MCD, 9 were composed of gray matter heterotopia and 7 of cortical dysplasia. MR spectroscopy of both MCD lesions and NACS (n=10) showed decreased NAA/Cr compared with that of the control group. NACS in these patients did not present significant differences regarding NAA/Cr in comparison with the affected side. CONCLUSIONS: MR spectroscopy demonstrated abnormal NAA/Cr in both MCD lesions and NACS in patients harboring focal MCD, giving support to the hypothesis that in MCD metabolic abnormalities extend far away from the limits of the lesion, reaching the contralateral side.


Subject(s)
Aspartic Acid/analogs & derivatives , Cerebral Cortex/abnormalities , Cerebral Cortex/metabolism , Creatine/metabolism , Epilepsy/metabolism , Magnetic Resonance Spectroscopy/methods , Protons , Adolescent , Adult , Aspartic Acid/metabolism , Biomarkers/metabolism , Cerebral Cortex/growth & development , Child , Epilepsy/diagnosis , Female , Humans , Male , Tissue Distribution
9.
AJNR Am J Neuroradiol ; 27(1): 204-7, 2006 Jan.
Article in English | MEDLINE | ID: mdl-16418384

ABSTRACT

We describe how proton MR spectroscopy ((1)H-MR spectroscopy) was useful in elucidating the diagnosis of galactosemia in an undiagnosed 6-month-old infant. In vivo (1)H-MR spectroscopy of the brain showed a doublet at 3.7 parts per million, which was identified as galactitol (Gal-ol) by in vitro (1)H-MR spectroscopy of the urine. Galactosemia was subsequently confirmed by laboratory tests and treatment was initiated. A follow-up brain MR imaging and (1)H-MR spectroscopy study revealed resolution of white matter lesions and disappearance of Gal-ol peaks.


Subject(s)
Brain Chemistry , Galactitol/analysis , Galactosemias/diagnosis , Magnetic Resonance Spectroscopy , Brain/pathology , Female , Galactitol/urine , Galactosemias/diet therapy , Humans , Infant , Magnetic Resonance Imaging
10.
Mult Scler ; 12(6): 754-9, 2006 Dec.
Article in English | MEDLINE | ID: mdl-17263003

ABSTRACT

The aim of this study was to correlate diffusion to magnetization transfer (MT) magnetic resonance imaging (MRI) results in multiple sclerosis (MS), in order to establish if the former technique provides complementary information. Magnetization transfer ratio (MTR) and apparent diffusion coefficient (ADC) were measured in 156 different regions of interest (ROIs) of 14 MS patients, where 84 corresponded to T1 hypointense lesions, 60 to T1 isointense lesions and 12 to regions of normal appearing white matter (NAWM). MTR mean value was higher for T1 isointense than for T1 hypointense lesions, and lower when compared to NAWM. ADC mean value for T1 isointense lesions was higher than for NAWM, but lower than for T1 hypointense lesions. A significant negative correlation was found between ADC and MTR for hypointense lesions (Pearson's r = -0.758, P < 0.001), whereas this correlation was much weaker for T1 isointense lesions (Pearson's r= -0.256, P = 0.049). There was no correlation between ADC and MTR for NAWM. The fact that ADC and MTR show a strong correlation only for T1 hypointense lesions indicates that, when tissue integrity is not severely compromised, as in the case of T1 isointense lesions or NAWM, ADC and MTR might be sensitive to different pathological processes.


Subject(s)
Diffusion Magnetic Resonance Imaging , Magnetic Resonance Imaging , Multiple Sclerosis, Chronic Progressive/pathology , Multiple Sclerosis, Relapsing-Remitting/pathology , Adult , Diffusion , Disability Evaluation , Female , Humans , Male , Middle Aged , Severity of Illness Index
SELECTION OF CITATIONS
SEARCH DETAIL
...